Skip to main content
Clinical Trials/NCT00839319
NCT00839319
Completed
Phase 1

Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (Short Title (HOP-3)

University of Washington1 site in 1 country59 target enrollmentMarch 2009

Overview

Phase
Phase 1
Intervention
Acyline
Conditions
Healthy Males
Sponsor
University of Washington
Enrollment
59
Locations
1
Primary Endpoint
Serum Testosterone (T)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this investigational study is to determine how much male hormone, testosterone, is necessary to maintain sperm production in the testis. This knowledge will be used to help in the development of a safe male hormonal contraception.

Detailed Description

Three study drugs will be used in this study: Testim (testosterone gel), Human Chorionic Gonadotropin (hCG) and acyline. Testosterone is a naturally occurring hormone in men. When given to normal men, testosterone gel will temporarily lower the amount of testosterone in the testes and lower sperm counts. hCG is a female hormone produced during pregnancy that is similar to and has the same actions as a male hormone, luteinizing hormone (LH). Like LH, hCG stimulates the testis to produce testosterone and sperm, and is used in the treatment of men who are deficient in LH. When hCG is given together with testosterone to normal men, the amount of testosterone in the testes will change, dependent on the amount of hCG received. Some participants will receive placebo hCG injections (no active medication). Acyline suppresses LH (luteinizing hormone) and FSH (follicle stimulating hormone), which are hormones made by the pituitary gland in the brain, thus blocking the signal from the brain that causes the testes to make testosterone. Therefore, acyline blocks testosterone production. Men may experience some side effects from the low levels of testosterone caused by acyline. Acyline is an experimental drug. Testosterone gel and hCG are approved for use in men with low testosterone levels. The U.S. Food and Drug Administration (FDA) allows testosterone gel, hCG and acyline to be given in combination for research to a small number of volunteers. Over 125 men have received acyline. Both Acyline and hCG will be given by injection. Acyline injections are formulated by subjects weight and may be given in multiple injections. Participation will last approximately 2 months. The study involves a minimum of 9 visits in Seattle, WA. Clinic visits at Screening, Day 1 and Day 10 will take about 1-1.5 hours each. On Day 1 \& 10 a fine needle aspiration of one testis will be performed. The Day 7, Day 17, and Day 40 visits will take approximately 30 minutes. The other visits will take about 15 minutes each time. Over the course of the study, which includes 5 separate blood draws, approximately 12 ounces (one and a half cups) of blood will be drawn. Some of the study drugs will be given by injection. One drug is a topical gel. This is NOT a trial of a male contraceptive, and the study medications will not prevent pregnancy. Subjects must use an acceptable form of birth control.

Registry
clinicaltrials.gov
Start Date
March 2009
End Date
November 2010
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

John Amory

Professor, Department of Medicine

University of Washington

Eligibility Criteria

Inclusion Criteria

  • Males age 18-50
  • Normal serum testosterone, LH and FSH
  • PSA \< 4.0
  • Agrees not to donate blood or participate in another research study during the study
  • Informed consent
  • In general good health based on normal screening evaluation (consisting of a medical history, physical exam, normal sperm count, normal serum chemistry and hematology)
  • Must be willing to use a reliable form of contraception during the study

Exclusion Criteria

  • Oligospermia (sperm count \< 15 million/mL after 48 hours of abstinence) and/or abnormal motility or morphology.
  • Participation in a long-term male contraceptive study within the past three months
  • History of testosterone or anabolic steroid abuse in the past
  • Poor general health with significantly abnormal blood results
  • History of or current testicular disease
  • History of a bleeding disorder or need for anticoagulation
  • History of sleep apnea and/or major psychiatric problems
  • BMI \> 32
  • Subjects with a skin condition that might interfere or be exacerbated by testosterone gel use
  • Subject's with alcohol or drug use

Arms & Interventions

Acyline plus 125 IU hCG

Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days

Intervention: Acyline

Acyline plus Placebo

Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days

Intervention: Acyline

Acyline plus Placebo

Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days

Intervention: placebo hCG (no active ingredient)

Acyline plus 15 IU hCG

Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days

Intervention: Acyline

Acyline plus 15 IU hCG

Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days

Intervention: hCG (human chorionic gonadotropin)

Acyline plus 60 IU hCG

Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days

Intervention: Acyline

Acyline plus 60 IU hCG

Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days

Intervention: hCG (human chorionic gonadotropin)

Acyline plus 125 IU hCG

Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days

Intervention: hCG (human chorionic gonadotropin)

Acyline plus Testosterone gel

Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days

Intervention: Acyline

Acyline plus Testosterone gel

Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days

Intervention: Testosterone gel

Outcomes

Primary Outcomes

Serum Testosterone (T)

Time Frame: 10 days

Serum Luteinizing Hormone (LH)

Time Frame: 10 days

Serum Follicle Stimulating Hormone (FSH)

Time Frame: 10 days

Intratesticular Testosterone (ITT-T)

Time Frame: 10 days

Study Sites (1)

Loading locations...

Similar Trials